Home LiteratureArticle Details
PMID: 7474139 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.

Journal of virology ·Vol. 69 ·No. 11 ·1995-11-00 ·Pages 7180-6

Konvalinka J, Litterst MA, Welker R, Kottler H, Rippmann F, Heuser AM, Kräusslich HG

Abstract

Infectious retrovirus particles are derived from structural polyproteins which are cleaved by the viral proteinase (PR) during virion morphogenesis. Besides cleaving viral polyproteins, which is essential for infectivity, PR of human immunodeficiency virus (HIV) also cleaves cellular proteins and PR expression causes a pronounced cytotoxic effect. Retroviral PRs are aspartic proteases and contain two copies of the triplet Asp-Thr-Gly in the active center with the threonine adjacent to the catalytic aspartic acid presumed to have an important structural role. We have changed this threonine in HIV type 1 PR to a serine. The purified mutant enzyme had an approximately 5- to 10-fold lower activity against HIV type 1 polyprotein and peptide substrates compared with the wild-type enzyme. It did not induce toxicity on bacterial expression and yielded significantly reduced cleavage of cytoskeletal proteins in vitro. Cleavage of vimentin in mutant-infected T-cell lines was also markedly reduced. Mutant virus did, however, elicit productive infection of several T-cell lines and of primary human lymphocytes with no significant difference in polyprotein cleavage and with similar infection kinetics and titer compared with wild-type virus. The discrepancy between reduced processing in vitro and normal virion maturation can be explained by the observation that reduced activity was due to an increase in Km which may not be relevant at the high substrate concentration in the virus particle. This mutation enables us therefore to dissociate the essential function of PR in viral maturation from its cytotoxic effect.

MeSH Terms
Amino Acid Sequence Animals Binding Sites Blotting, Western Cell Line Cell Survival Chlorocebus aethiops Cytoskeletal Proteins/isolation & purification,metabolism Genes, pol HIV Protease/biosynthesis,metabolism HIV-1/enzymology,pathogenicity,physiology Humans Kinetics Molecular Sequence Data Mutagenesis, Site-Directed Peptide Fragments/chemistry,isolation & purification Recombinant Proteins/biosynthesis,metabolism Substrate Specificity Transfection
Chemicals
Cytoskeletal Proteins Peptide Fragments Recombinant Proteins HIV Protease
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Konvalinka J
Angewandte Tumorvirologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Litterst M A
Welker R
Kottler H
Rippmann F
Heuser A M
Kräusslich H G
References (39)
39 references, click to expand
  1. Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes.
    Virology. 1983 Aug;129(1):51-64 PMID: 6412453
  2. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.
    Science. 1989 Aug 11;245(4918):616-21 PMID: 2548279
  3. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.
    Science. 1985 Aug 9;229(4713):563-6 PMID: 2992081
  4. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
    J Virol. 1986 Aug;59(2):284-91 PMID: 3016298
  5. Standardized and simplified nomenclature for proteins common to all retroviruses.
    J Virol. 1988 May;62(5):1808-9 PMID: 3357211
  6. Use of T7 RNA polymerase to direct expression of cloned genes.
    Methods Enzymol. 1990;185:60-89 PMID: 2199796
  7. Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein.
    Proc Natl Acad Sci U S A. 1990 Aug;87(16):6336-40 PMID: 2201025
  8. Proteolytic cleavage of microtubule-associated proteins by retroviral proteinases.
    J Gen Virol. 1990 Sep;71 ( Pt 9):1985-91 PMID: 2212989
  9. Expression in Escherichia coli and purification of human immunodeficiency virus type 1 capsid protein (p24).
    AIDS Res Hum Retroviruses. 1990 Oct;6(10):1169-75 PMID: 2123631
  10. Specificity studies on retroviral proteinase from myeloblastosis-associated virus.
    Biochemistry. 1991 Apr 9;30(14):3437-43 PMID: 1849425
  11. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3213-7 PMID: 2014242
  12. Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection.
    Nature. 1991 Apr 18;350(6319):625-6 PMID: 2017258
  13. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.
    Proc Natl Acad Sci U S A. 1991 May 15;88(10):4528-32 PMID: 2034693
  14. Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1 beta as substrates of the protease from human immunodeficiency virus.
    J Biol Chem. 1991 Aug 5;266(22):14548-53 PMID: 1907279
  15. Role of the gag and pol genes of human immunodeficiency virus in the morphogenesis and maturation of retrovirus-like particles expressed by recombinant vaccinia virus: an ultrastructural study.
    J Gen Virol. 1991 Oct;72 ( Pt 10):2509-17 PMID: 1919528
  16. Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation.
    J Virol. 1992 Jan;66(1):567-72 PMID: 1727499
  17. Analysis of HIV particle formation using transient expression of subviral constructs in mammalian cells.
    Virology. 1992 Jan;186(1):25-39 PMID: 1727601
  18. Rational design of peptide-based HIV proteinase inhibitors.
    Science. 1990 Apr 20;248(4953):358-61 PMID: 2183354
  19. Sensitive, soluble chromogenic substrates for HIV-1 proteinase.
    J Biol Chem. 1990 May 15;265(14):7733-6 PMID: 2186027
  20. The structure and function of the aspartic proteinases.
    Annu Rev Biophys Biophys Chem. 1990;19:189-215 PMID: 2194475
  21. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S.
    J Biol Chem. 1991 Dec 25;266(36):24359-66 PMID: 1761538
  22. An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase.
    EMBO J. 1992 Mar;11(3):1141-4 PMID: 1547777
  23. Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates.
    J Biol Chem. 1992 May 15;267(14):9491-8 PMID: 1315756
  24. Cleavage of bovine brain microtubule-associated protein-2 by human immunodeficiency virus proteinase.
    J Neurochem. 1992 Sep;59(3):874-80 PMID: 1494913
  25. Degradation of cytoskeletal proteins by the human immunodeficiency virus type 1 protease.
    Cell Biol Int Rep. 1992 Jul;16(7):603-12 PMID: 1516138
  26. Structural studies of the retroviral proteinase from avian myeloblastosis associated virus.
    Proteins. 1992 Nov;14(3):382-91 PMID: 1332025
  27. Proteolytic processing of Ty3 proteins is required for transposition.
    J Virol. 1993 Jan;67(1):19-28 PMID: 7677953
  28. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase.
    Virology. 1993 Feb;192(2):605-17 PMID: 8421902
  29. Myeloblastosis associated virus (MAV) proteinase site-mutated to be HIV-like has a higher activity and allows production of infectious but morphologically altered virus.
    Virology. 1993 Feb;192(2):667-72 PMID: 7678476
  30. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.
    J Virol. 1993 Jul;67(7):4050-5 PMID: 8510215
  31. Structure-based inhibitors of HIV-1 protease.
    Annu Rev Biochem. 1993;62:543-85 PMID: 8352596
  32. Proteolytic processing of particle-associated retroviral polyproteins by homologous and heterologous viral proteinases.
    Eur J Biochem. 1995 Feb 15;228(1):191-8 PMID: 7883003
  33. Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.
    J Virol. 1995 May;69(5):2751-8 PMID: 7535864
  34. Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein.
    J Virol. 1995 Nov;69(11):7264-8 PMID: 7474150
  35. Active human immunodeficiency virus protease is required for viral infectivity.
    Proc Natl Acad Sci U S A. 1988 Jul;85(13):4686-90 PMID: 3290901
  36. Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines.
    J Exp Med. 1988 Aug 1;168(2):605-21 PMID: 3261775
  37. Viral proteinases.
    Annu Rev Biochem. 1988;57:701-54 PMID: 3052288
  38. Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates.
    J Biol Chem. 1989 Feb 25;264(6):3428-35 PMID: 2536748
  39. Rapid and efficient site-specific mutagenesis without phenotypic selection.
    Proc Natl Acad Sci U S A. 1985 Jan;82(2):488-92 PMID: 3881765
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1995-11-00
Pages
7180-6
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC189639
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com